KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Accounts Payables: 2019-2024

Historic Accounts Payables for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $13.4 million.

  • Royalty Pharma's Accounts Payables rose 87.78% to $41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.4 million, marking a year-over-year increase of 87.78%. This contributed to the annual value of $13.4 million for FY2024, which is 11.84% down from last year.
  • Royalty Pharma's Accounts Payables amounted to $13.4 million in FY2024, which was down 11.84% from $15.2 million recorded in FY2023.
  • Royalty Pharma's Accounts Payables' 5-year high stood at $15.2 million during FY2023, with a 5-year trough of $5.6 million in FY2021.
  • For the 3-year period, Royalty Pharma's Accounts Payables averaged around $12.1 million, with its median value being $13.4 million (2024).
  • Per our database at Business Quant, Royalty Pharma's Accounts Payables plummeted by 47.84% in 2021 and then skyrocketed by 91.82% in 2023.
  • Over the past 5 years, Royalty Pharma's Accounts Payables (Yearly) stood at $10.8 million in 2020, then plummeted by 47.84% to $5.6 million in 2021, then surged by 40.68% to $7.9 million in 2022, then spiked by 91.82% to $15.2 million in 2023, then decreased by 11.84% to $13.4 million in 2024.